BPI Staff

July 22, 2019

1 Min Read

Today’s cell and gene therapies are proving themselves to be viable
entities. However, as more products leave the clinic for commercialization, new questions emerge: Is enough manufacturing capacity available? How do companies
reduce cost of goods (CoG) and increase manufacturing efficiency? Should a developer build its own capabilities or use a third party? What benefits can a contract development and manufacturing organization (CDMO) bring to this space?

BioProcess Insider editor Dan Stanton posed these questions to a range of industry leaders during a rountable discussion at the Wednesday, 5 June 2019, session of the BPI Theater at BIO. Panelists included Joseph Rininger, director of cell and gene therapy at the Latham Biopharm Group; Felix Hsu, senior vice president and global head at WuXi Advanced Therapies; Soenke Brunswieck, vice president of cell and gene therapies at the Celonic Group; and Joe Vitale, director and account management at Hitachi Chemical.

Watch the full roundtable discussion below and leave your thoughts or questions on the topic below in the comments.

You May Also Like